Duchenne Muscular Dystrophy Therapeutics Market CAGR At 28 9 Percent And See Huge Growth For New Business Stratergies 2023-2030 Report By Business Gro menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Santhera Secures Additional Funding Through a Private Placement of Shares and Upsizing of Existing Financing Arrangement pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Investegate announcements from Santhera Pharmaceuticals Holdi, Santhera Announces Preliminary 2021 Financial Results and Increases Issued Share Capital to Create Treasury Shares for Future Financing
Santhera Pharmaceuticals (SIX: SANN) announces preliminary 2021 financial results and operational progress made. The Company is on track to start a rolling NDA submission for vamorolone in DMD at the end of March. With a cash balance of CHF 18 million (February 28, 2022), the announced increase of share issuances .
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. Ad hoc announcement pursuant to Art. 53 LR Initiation of rolling